

New injectable antibiotic for respiratory diseases of pigs – comparisons with Tiamutin®

“Take home” messages

- Pfizer Animal Health has introduced in the EU a new injectable antibiotic “DRAXXIN” (TULATHROMYCIN), a new triamilide antibiotic.
- Triamilides are a sub-class of macrolides and share patterns of resistance with other macrolides, lincosamides and group B. streptogramins.
- Draxxin is a single shot antibiotic in pigs for intramuscular use against respiratory disease associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida* and *Mycoplasma hyopneumoniae*.
- A long withdrawal period (33 days) has been allocated for pigs (meat and offal).
- The pleuromutilins, unlike Draxxin, are unrelated to human use antibiotics.
- The pleuromutilins, unlike Draxxin, are effective against *Haemophilus parasuis* and *Streptococcus suis*, which are frequently involved in respiratory disease of pigs.
- The pleuromutilins, unlike Draxxin, are effective against enteric pathogens e.g. *Brachyspira hyodysenteriae*, *Brachyspira pilosicoli* and *Lawsonia intracellularis*, in addition to mycoplasma and other non-viral respiratory pathogens.
- Tiamutin injectable, unlike Draxxin, is approved for use in sows/gilts.
- Tiamutin injectable, unlike Draxxin, may safely be used simultaneously, if desired, in pigs receiving other medications e.g. tetracyclines (however monovalent cationic ionophores such as monensin are the exception).
- Draxxin, by contrast, may not be used simultaneously with other macrolides or lincosamides or with other veterinary medicinal products.

TIAMULIN
tiamutin[®]
the original – tried, tested, trusted





To report the introduction of a new antibiotic for veterinary medicine is a rare event! However early in 2004 Pfizer Animal Health introduced “Draxxin” in the EU as a ready to use injectable with claims for the treatment of respiratory disease in pigs associated with:

Actinobacillus pleuropneumoniae
Pasteurella multocida
Mycoplasma hyopneumoniae




strains sensitive to the active ingredient **TULATHROMYCIN**. It is a direct competitor therefore, in the porcine respiratory disease market segment for “Tiamutin” injectable.

For background information the following items are appended:

- i) EU approved Data Sheet as released in UK
- ii) Abstracts of 3 papers presented at the Congress of the European Association for Veterinary Pharmacology and Toxicology (EAVPT) Meeting (2003)
- iii) The current journal advertisement. Veterinary Record (31/01/04)

Tulathromycin belongs to a new class of antimicrobials, the triamilides, which are a sub-class of macrolides. It is a semi-synthetic macrolide with a claimed prolonged duration of action. Cross-resistance with other macrolides and with lincosamides e.g. lincomycin and Group B streptogramin antibiotics e.g. quinupristin/dalfopristin -“Synercid” occurs.

(“Synercid” is especially important in human medicine because of its value in treating resistant infections in hospitalized patients e.g. methicillin-resistant *Staphylococcus aureus*-MRSA.)



Dr Ulrich Klein
International Technical Services
Manager, Pig Products



Dr David Miller
Demafarma Consultancy Ltd

Further information on the Tiamutin® (tiamulin) range of products is available from the Pig Products Manager at Novartis Animal Health operations in over 50 countries worldwide.